CareDx Stock Spikes on News of MolDX Reimbursement of AlloSure

Sep 26, 2017

|

NEW YORK (GenomeWeb) – CareDx's shares soared as high as 34 percent in morning trading on the Nasdaq after the company announced that Palmetto GBA's Molecular Diagnostics Services (MolDX) Program had set reimbursement for the firm's AlloSure cfDNA-based organ transplant test diagnostic at $2,840.75.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Australia's Gene Editing Policy Approach

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

Just "Preliminary" Work

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Some Big Trees

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

This Week in PNAS

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.

Menu